HRP20020088B1 - Levodopa/karbidopa/entakapon farmaceutski pripravak - Google Patents

Levodopa/karbidopa/entakapon farmaceutski pripravak

Info

Publication number
HRP20020088B1
HRP20020088B1 HR20020088A HRP20020088A HRP20020088B1 HR P20020088 B1 HRP20020088 B1 HR P20020088B1 HR 20020088 A HR20020088 A HR 20020088A HR P20020088 A HRP20020088 A HR P20020088A HR P20020088 B1 HRP20020088 B1 HR P20020088B1
Authority
HR
Croatia
Prior art keywords
levodopa
carbidopa
entacapone
pharmaceutical preparation
pharmaceutically acceptable
Prior art date
Application number
HR20020088A
Other languages
English (en)
Inventor
Kallioinen Sari
Kervinen Lasse
Laaksonen Marja
Lintulaakso Jarmo
Niskanen Mervi
Partanen Marja
Ritala Marja
Vahervuo Kari
Virkki Matti
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8554988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20020088(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of HRP20020088A2 publication Critical patent/HRP20020088A2/xx
Publication of HRP20020088B1 publication Critical patent/HRP20020088B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Kruti oralni pripravak koji sadrži farmakološki učinkovite količine entakapona, levodope i karbidope ili njihovih farmaceutski prihvatljivih soli ilihidrata, i farmaceutski prihvatljivu podlogu, naznačen time, da se bitni udio karbidope nalazi odvojen od entakapona i levodope, pri čemu se terapeutski učinak koji se postiže s navedenim pripravkom u liječenju Parkinsonove bolesti može usporediti sonim postignutim s odijeljenim formulacijama entakapona i levodopa-karbidopa koje se primjenjuju uzastopno u istim dozama aktivnih supstanci kao i navedeni kruti oralni pripravak. Patent sadrži još 25 patentnih zahtjeva.
HR20020088A 1999-06-30 2002-01-29 Levodopa/karbidopa/entakapon farmaceutski pripravak HRP20020088B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI991485A FI109453B (fi) 1999-06-30 1999-06-30 Farmaseuttinen koostumus
PCT/FI2000/000593 WO2001001984A1 (en) 1999-06-30 2000-06-29 Levodopa / carbidopa / entacapone pharmaceutical preparation

Publications (2)

Publication Number Publication Date
HRP20020088A2 HRP20020088A2 (en) 2005-10-31
HRP20020088B1 true HRP20020088B1 (hr) 2007-05-31

Family

ID=8554988

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020088A HRP20020088B1 (hr) 1999-06-30 2002-01-29 Levodopa/karbidopa/entakapon farmaceutski pripravak

Country Status (42)

Country Link
US (2) US6500867B1 (hr)
EP (1) EP1189608B1 (hr)
JP (2) JP4204783B2 (hr)
KR (1) KR100905428B1 (hr)
CN (1) CN1168440C (hr)
AR (1) AR033796A1 (hr)
AT (1) ATE245417T1 (hr)
AU (1) AU765932B2 (hr)
BG (1) BG65364B1 (hr)
BR (2) BRPI0011867B8 (hr)
CA (1) CA2378469C (hr)
CO (1) CO5180579A1 (hr)
CZ (2) CZ303010B6 (hr)
DE (1) DE60004052T2 (hr)
DK (1) DK1189608T3 (hr)
EA (1) EA004503B1 (hr)
EE (1) EE05473B1 (hr)
ES (1) ES2203495T3 (hr)
FI (1) FI109453B (hr)
FR (1) FR2797587A1 (hr)
GE (1) GEP20043314B (hr)
HK (1) HK1047040B (hr)
HR (1) HRP20020088B1 (hr)
HU (1) HU230395B1 (hr)
IL (1) IL146807A (hr)
IT (1) ITMI20001450A1 (hr)
ME (1) ME00520B (hr)
MX (1) MXPA01013167A (hr)
MY (1) MY127685A (hr)
NO (2) NO330260B1 (hr)
NZ (1) NZ515780A (hr)
PE (1) PE20010399A1 (hr)
PL (1) PL197818B1 (hr)
PT (1) PT1189608E (hr)
RS (1) RS50368B (hr)
SI (1) SI1189608T1 (hr)
SK (1) SK286451B6 (hr)
TR (1) TR200103763T2 (hr)
TW (1) TWI241187B (hr)
UA (1) UA75047C2 (hr)
WO (1) WO2001001984A1 (hr)
ZA (1) ZA200109868B (hr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
CA2501345A1 (en) * 2002-10-11 2004-04-22 Depomed Development, Ltd. Gastro-retentive levodopa delivery form
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2006037061A2 (en) * 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
WO2006051154A1 (en) 2004-11-10 2006-05-18 Orion Corporation Treatment of restless legs syndrome
AU2012216377C1 (en) * 2005-06-08 2013-10-10 Orion Corporation Oral dosage form
MX2007015377A (es) * 2005-06-08 2008-02-14 Orion Corp Forma de dosificacion oral.
WO2007002516A2 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
CN102816157B (zh) 2005-07-26 2016-05-18 比艾尔-坡特拉有限公司 作为comt抑制剂的硝基儿茶酚衍生物
US8877802B2 (en) * 2005-07-28 2014-11-04 Duke Univerity Antiparkinsonian action of phenylisopropylamines
EP1948153A2 (en) * 2005-09-21 2008-07-30 Orion Corporation Treatment of symptoms of parkinson`s disease
EP1945188A2 (en) * 2005-11-07 2008-07-23 Teva Pharmaceutical Industries Ltd. Levodopa compositions
EP1954256A2 (en) * 2005-11-09 2008-08-13 Torrent Pharmaceuticals Ltd Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
CN100384411C (zh) * 2006-03-17 2008-04-30 北京科信必成医药科技发展有限公司 卡左双多巴口腔崩解片
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
EP2104424A4 (en) 2006-10-30 2011-06-15 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA
US20100316712A1 (en) * 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008081268A2 (en) * 2006-12-27 2008-07-10 Wockhardt Research Centre Pharmaceutical compositions of entacapone
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
LT2481410T (lt) 2007-01-31 2016-11-10 Bial - Portela & Ca., S.A. Nitrokatecholio dariniai kaip komt inhibitoriai vartojami konkrečiu dozavimo režimu
US20110171275A1 (en) * 2007-08-20 2011-07-14 Team Academy Of Pharmaceutical Science Gastroretentive drug delivery system, preparation method and use thereof
NZ587169A (en) * 2008-02-06 2011-03-31 Wockhardt Research Center Pharmaceutical compositions of entacapone co-micronized with sugar alcohols
EP2252284B1 (en) * 2008-02-06 2011-05-25 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
US8975410B2 (en) 2008-03-17 2015-03-10 BIAL—Portela & CA., S.A. Crystal forms of 5-[3-(2,5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4] oxadiazol-5-yl]-3-nitrobenzene-1,2-diol
WO2010020969A1 (en) * 2008-08-22 2010-02-25 Wockhardt Research Centre An extended release pharmaceutical composition of entacapone or salts thereof
US20110229566A1 (en) 2008-08-22 2011-09-22 Yatendra Kumar Gupta Single Unit Oral Dose Pharmaceutical Composition Comprising Levodopa, Carbidopa And Entacapone Or Salts Thereof
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
CN105878242A (zh) 2009-04-01 2016-08-24 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
LT2432454T (lt) 2009-05-19 2017-07-10 Neuroderm Ltd Kompozicijos, skirtos nepertraukiamam dopa dekarboksilazės inhibitorių vartojimui
EP2517704B1 (en) * 2009-12-25 2019-05-01 Innopharmax, Inc. Pharmaceutical composition for treating parkinson's disease and preparation method thereof
US20130137729A1 (en) * 2010-03-04 2013-05-30 Orion Corporation Use of levodopa, carbidopa and entacapone for treating parkinson's disease
DE102010023828A1 (de) 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
NZ610911A (en) * 2010-11-15 2015-02-27 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012147099A1 (en) 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
CN103476406B (zh) * 2011-04-26 2017-05-24 因华生技制药股份有限公司 安它可朋组合物
BR112014014341A2 (pt) 2011-12-13 2017-08-22 Bial Portela & Ca Sa Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
MX2014014902A (es) 2012-06-05 2015-03-04 Neuroderm Ltd Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
HRP20211442T1 (hr) * 2013-03-13 2022-02-04 Neuroderm Ltd Kombinacija za liječenje parkinsonove bolesti
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
HRP20231716T1 (hr) 2014-03-13 2024-03-15 Neuroderm Ltd. Pripravci inhibitora dopa dekarboksilaze
US10071069B2 (en) * 2014-09-04 2018-09-11 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
EP3236957A1 (en) 2014-12-23 2017-11-01 Pharmathen S.A. Levodopa/carbidopa/entacapone pharmaceutical preparation and method for preparing the same
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
WO2018011181A1 (en) * 2016-07-11 2018-01-18 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia
EP3500246B1 (en) 2016-08-18 2021-08-04 Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi Antiparkinson tablet formulation with improved dissolution profile
WO2019145773A1 (en) 2017-12-15 2019-08-01 Nos Life Sciences Corporation Liposomal-encapsulated formulations
KR20200136008A (ko) 2018-03-23 2020-12-04 롭서 파마슈티컬스 악티에볼라그 신경퇴행성 장애의 치료를 위한 약제학적 조성물의 연속 투여
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB2321190B (en) 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
US6599530B2 (en) 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus

Also Published As

Publication number Publication date
EE200100716A (et) 2003-02-17
ITMI20001450A1 (it) 2001-12-28
DK1189608T3 (da) 2003-11-10
ME00520B (me) 2011-10-10
IL146807A (en) 2006-10-05
BG65364B1 (bg) 2008-04-30
JP4885896B2 (ja) 2012-02-29
US20030017201A1 (en) 2003-01-23
NO20110090L (no) 2002-02-25
KR100905428B1 (ko) 2009-06-30
EP1189608A1 (en) 2002-03-27
SK286451B6 (sk) 2008-10-07
MY127685A (en) 2006-12-29
FI991485A0 (fi) 1999-06-30
CN1358090A (zh) 2002-07-10
HRP20020088A2 (en) 2005-10-31
MXPA01013167A (es) 2002-07-02
CO5180579A1 (es) 2002-07-30
HK1047040B (zh) 2005-04-29
FI991485A (fi) 2000-12-31
PE20010399A1 (es) 2001-04-10
GEP20043314B (en) 2004-02-10
UA75047C2 (en) 2006-03-15
BRPI0011867B8 (pt) 2021-05-25
FR2797587A1 (fr) 2001-02-23
AU765932B2 (en) 2003-10-02
YU92501A (sh) 2004-09-03
NO330260B1 (no) 2011-03-14
JP2008156373A (ja) 2008-07-10
CA2378469A1 (en) 2001-01-11
EA200200106A1 (ru) 2002-06-27
RS50368B (sr) 2009-11-10
US6500867B1 (en) 2002-12-31
HK1047040A1 (en) 2003-02-07
EA004503B1 (ru) 2004-04-29
CZ304416B6 (cs) 2014-04-23
JP4204783B2 (ja) 2009-01-07
CN1168440C (zh) 2004-09-29
JP2003503454A (ja) 2003-01-28
DE60004052T2 (de) 2004-04-15
NO20016203L (no) 2002-02-25
TWI241187B (en) 2005-10-11
ZA200109868B (en) 2003-05-28
ITMI20001450A0 (it) 2000-06-28
CZ303010B6 (cs) 2012-02-29
ES2203495T3 (es) 2004-04-16
PT1189608E (pt) 2003-12-31
EP1189608B1 (en) 2003-07-23
CA2378469C (en) 2009-10-06
NZ515780A (en) 2004-06-25
AR033796A1 (es) 2004-01-07
BR0011867A (pt) 2002-03-05
BG106251A (en) 2002-08-30
HUP0202273A3 (en) 2002-11-28
PL352775A1 (en) 2003-09-08
SK19232001A3 (sk) 2002-06-04
FI109453B (fi) 2002-08-15
HUP0202273A2 (en) 2002-10-28
EE05473B1 (et) 2011-10-17
NO20016203D0 (no) 2001-12-18
WO2001001984A1 (en) 2001-01-11
PL197818B1 (pl) 2008-04-30
TR200103763T2 (tr) 2002-04-22
DE60004052D1 (de) 2003-08-28
ATE245417T1 (de) 2003-08-15
HU230395B1 (hu) 2016-04-28
BRPI0011867B1 (pt) 2019-01-08
SI1189608T1 (en) 2004-04-30
CZ20014636A3 (cs) 2002-05-15
US6797732B2 (en) 2004-09-28
KR20020010155A (ko) 2002-02-02
AU5830600A (en) 2001-01-22

Similar Documents

Publication Publication Date Title
HRP20020088B1 (hr) Levodopa/karbidopa/entakapon farmaceutski pripravak
YU49698A (sh) Smeše koje sadrže tetrahidrolipstatin
GEP20022784B (en) Celecoxib Composition
ATE252892T1 (de) Aus mehreren einzeleinheiten zusammengesetzte arzneimittel mit nicht-steroidalen wirkstoffen (nsaids)
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
NZ503946A (en) Oral dosage form in an oval or caplet shape for administration of bisphosphonates and other known medicaments
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
PT1037648E (pt) Utilizacao de preparados de eritropoietina e ferro para a producao de preparados de combinacao farmaceutica para o tratamento de doencas reumaticas
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
AP2003002763A0 (en) Controlled release formulations for oral administration
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
JP2002540148A5 (hr)
BE2016C017I2 (hr)
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
DK0927031T3 (da) Farmaceutisk sammensætning indeholdende nimesulid til oral admnistration
IT1293835B1 (it) Composizioni farmaceutiche orali in forma solida a cessione modulata contenenti nicorandil e procedimento per la loro preparazione
EA200300430A1 (ru) Новые фармацевтические композиции, содержащие эпинастин и псевдоэфедрин
HUP9800623A2 (hu) (+)-O-demetil-tramadol felhasználása fájdalomcsillapító hatású orális gyógyszerkészítmények előállítására
DE60112578D1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
PE20011042A1 (es) Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan
ECSP982396A (es) Composiciones que contienen tetrahidrolipstatina
RU99112967A (ru) Способ лечения и профилактики дизентерии свиней
GEP20063804B (en) Once-a-day oxycodone formulations

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190614

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20200629